INMUNOFERON, A POTENTIAL BENEFICIAL TREATMENT FOR ME/CFS AND LYME DISEASE?
Here's a brief review on the effects of Inmunoferon on the immune system: this compound has shown "in vivo" to decrease inflammation after exercise in professional athletes by lowering TNF-alpha and IL-6. However it should not be considered an anti-inflammatory agent, but a promoter of a healthy immune system. Accordingly, it has shown "in vivo" to restore the insufficient T cell activation seen in COPD patients, especifically restoring the proper secretion of IFN-gamma by CD8+ cells.
Moreover, another study also shows a 43% increase in NK cell function, a 43%-49.7% increase in phagocytic activity of monocytes and a 33.1% enhancement in phagocytic activity of PBMCs (T and B cells, NK cells and monocytes) in COPD patients taking Inmunoferon for 90 days at dosages of 3 gr daily. Similarly, a study of patients of middle age with chronic bronchitis showed: 1. Number and activity of PBMCs increased by 10.6 % and by 11%, respectively, after 60 days; 2. Percentages in peripheral blood NK cells increased by 59.5% (reaching values of young health adults); 3. Activity of NK cells increased by approximately 400%.
Further details on the mechanisms by which Inmunoferon works have been shown "in vitro", demonstrating that Inmunoferon stimulated maturation of Dendritic Cells (DCs) showed by enhancement of co-stimulatoy and MHC-II receptors. In agreement, the stimulated DCs also increased proliferation of allogenic T cells, mediated by stimulation of TLR-4 and NF-kB translocation.
So, given that in ME/CFS and in chronic Lyme disease, many of these immune aberrations have been described, including high TNF-alpha and low NK cells, the Inmunoferon might be beneficial for this disease. (I haven't however heard of any patient with ME/CFS or Lyme diseas trying it as of yet).
I hope this is useful,
Sergio
Bibliography:
https://pubmed.ncbi.nlm.nih.gov/16608770
https://pubmed.ncbi.nlm.nih.gov/25369272
https://pubmed.ncbi.nlm.nih.gov/16537848
https://pubmed.ncbi.nlm.nih.gov/11401877
https://pubmed.ncbi.nlm.nih.gov/9049659/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2439514/
Here's a brief review on the effects of Inmunoferon on the immune system: this compound has shown "in vivo" to decrease inflammation after exercise in professional athletes by lowering TNF-alpha and IL-6. However it should not be considered an anti-inflammatory agent, but a promoter of a healthy immune system. Accordingly, it has shown "in vivo" to restore the insufficient T cell activation seen in COPD patients, especifically restoring the proper secretion of IFN-gamma by CD8+ cells.
Moreover, another study also shows a 43% increase in NK cell function, a 43%-49.7% increase in phagocytic activity of monocytes and a 33.1% enhancement in phagocytic activity of PBMCs (T and B cells, NK cells and monocytes) in COPD patients taking Inmunoferon for 90 days at dosages of 3 gr daily. Similarly, a study of patients of middle age with chronic bronchitis showed: 1. Number and activity of PBMCs increased by 10.6 % and by 11%, respectively, after 60 days; 2. Percentages in peripheral blood NK cells increased by 59.5% (reaching values of young health adults); 3. Activity of NK cells increased by approximately 400%.
Further details on the mechanisms by which Inmunoferon works have been shown "in vitro", demonstrating that Inmunoferon stimulated maturation of Dendritic Cells (DCs) showed by enhancement of co-stimulatoy and MHC-II receptors. In agreement, the stimulated DCs also increased proliferation of allogenic T cells, mediated by stimulation of TLR-4 and NF-kB translocation.
So, given that in ME/CFS and in chronic Lyme disease, many of these immune aberrations have been described, including high TNF-alpha and low NK cells, the Inmunoferon might be beneficial for this disease. (I haven't however heard of any patient with ME/CFS or Lyme diseas trying it as of yet).
I hope this is useful,
Sergio
Bibliography:
https://pubmed.ncbi.nlm.nih.gov/16608770
https://pubmed.ncbi.nlm.nih.gov/25369272
https://pubmed.ncbi.nlm.nih.gov/16537848
https://pubmed.ncbi.nlm.nih.gov/11401877
https://pubmed.ncbi.nlm.nih.gov/9049659/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2439514/